β2AR antagonists and β2AR gene deletion both promote skin wound repair processes

Christine E Pullar1, Gabrielle S Le Provost, Andrew P O'Leary

  • 1Deparment of Cell Physiology and Pharmacology, University of Leicester, Leicester, UK. cp161@le.ac.uk

Insights

Blocking the beta-2 adrenergic receptor (β2AR) speeds up skin wound repair by improving blood vessel growth and skin cell regeneration. This finding offers a new therapeutic target for faster healing.

Area of Science:

  • Dermatology
  • Regenerative Medicine
  • Pharmacology

Background:

  • Skin wound healing involves complex cellular and biological processes.
  • A functional beta-2 adrenergic receptor (β2AR) network exists in skin, but its role in healing is unclear.

Purpose of the Study:

  • To investigate the role of β2AR in skin wound healing.
  • To determine if β2AR blockade or deletion impacts the wound repair process.

Main Methods:

  • Utilized in vitro, ex vivo, and in vivo models, including murine wild-type and β2AR knockout excisional wound models.
  • Assessed angiogenesis, fibroblast function, re-epithelialization, inflammation, and cell motility.
  • Measured vascular endothelial growth factor (VEGF) secretion.

Main Results:

  • Blockade or genetic deletion of β2AR significantly promoted wound repair.
  • β2AR antagonism increased angiogenesis, dermal fibroblast function, and re-epithelialization.
  • Enhanced keratinocyte VEGF secretion and cell motility, accelerating early-stage wound repair.

Conclusions:

  • β2AR antagonism promotes early-stage skin wound repair.
  • Targeting β2AR represents a potential therapeutic strategy for enhancing wound healing.

Related Concept Videos

Overview of Regeneration and Repair01:19

Overview of Regeneration and Repair

Regeneration and repair processes are critical in healing damages caused by injury, disease, and aging. In regeneration, the damaged tissue is entirely replaced with new growth that restores the original architecture and function. In contrast, tissue repair usually results in a fixed tissue architecture involving scar formation. Scars generally do not reestablish tissue function and may also exhibit structural abnormalities at the injury site.
Regeneration
All animals have varying degrees of...
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...
Phases of Wound Repair01:28

Phases of Wound Repair

Following injury, the integrity of the injured tissues must be reestablished. For example, in skin tissue, wound repair involves coordination among resident skin cells, blood mononuclear cells, extracellular matrix, growth factors, and cytokines to complete the healing cascade.
Formation of Blood Clot
In case of deep injuries, trauma to blood vessels results in blood loss. In the meantime, phospholipids released from the ruptured endothelial cellular membrane are converted into arachidonic...
Antiasthma Drugs: β2-Adrenoceptor Agonists01:25

Antiasthma Drugs: β2-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce relaxation in these...
Long-patch Base Excision Repair01:02

Long-patch Base Excision Repair

Since the discovery of the two BER pathways, there has been a debate about how a cell chooses one pathway over the other and the factors determining this selection. Numerous in vitro experiments have pointed out multiple determinants for the sub-pathway selection. These are:
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...